ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.